{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"158"},{"groupId":"OG002","value":"70"}],"units":"Participants"}],"description":"Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable signs, symptoms, or medical conditions that occurred after the participant's signed informed consent was obtained. Abnormal laboratory values or test results occurring after informed consent constituted adverse events only if they induced clinical signs or symptoms, were considered clinically significant, required therapy (e.g., hematologic abnormality that required transfusion or hematological stem cell support), or required changes in study medication(s). TEAEs were defined as those AEs that started or worsened during the on-treatment period (either randomized or cross-over period).","groups":[{"description":"Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).","id":"OG000","title":"Ruxolitinib"},{"description":"Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.","id":"OG001","title":"Best Available Therapy"},{"description":"Participants from the BAT arm at the end of Cycle 6 crossed over to ruxolitinib treatment.","id":"OG002","title":"Ruxolitinib Cross-Over Period"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Set. Six participants in the BAT arm discontinued before receiving the first dose.","reportingStatus":"POSTED","timeFrame":"from Baseline to LPLV (approximately 5 years)","title":"Number of Participants With Any Treatment-emergent Adverse Event (TEAE)","type":"SECONDARY","unitOfMeasure":"Participants"}